# Effects of ginkgo diterpene lactone glucosamine combined with clopidogrel on hemodynamics, neurocytokines, and inflammatory responses in patients with cerebral infarction complicated by coronary heart disease

## TL;DR

Combining Ginkgo Diterpene Lactone Meglumine with Clopidogrel improves blood flow and reduces inflammation in patients with cerebral infarction and coronary heart disease.

## Contribution

Demonstrates that combining GM with CLO provides better outcomes than CLO alone in patients with cerebral infarction and CHD.

## Key findings

- The combination group showed greater improvement in hemodynamic parameters compared to CLO alone.
- The combination therapy reduced inflammatory markers and improved neurological function.
- No significant adverse reactions were observed in either group.

## Abstract

This study investigates the effects of Ginkgo Diterpene Lactone Meglumine (GM) combined with Clopidogrel (CLO) on hemodynamics, neurocytokines, and inflammatory responses in patients with cerebral infarction (CI) complicated by coronary heart disease (CHD).

A total of 152 patients diagnosed with CI complicated by CHD, admitted to our hospital between January 2024 and October 2024, were enrolled in the study. Among them, 81 patients received CLO monotherapy (control group), while the remaining 71 patients were treated with a combination of CLO and GM (observation group). Hemodynamic parameters, including plasma viscosity (PV), whole blood high (WBHSV) and low shear viscosity (WBLSV), as well as reduced viscosity (RV), were measured before and after treatment. Platelet adhesion test (PAdT) and platelet aggregation test (PAgT) were also performed. Inflammatory markers and neurocytokines were assessed using enzyme-linked immunosorbent assays, and adverse reactions during treatment were documented.

After treatment, both groups exhibited significant reductions in PAdT, PAgT, PV, WBHSV, WBLSV, and RV compared to baseline (P<0.05). However, PAdT, PAgT, WBHSV, WBLSV and RV were lower in the observation group compared to the control group (P<0.05). Additionally, the observation group showed lower levels of neuron-specific enolase, glial fibrillary acidic protein, tumor necrosis factor-a, and hypersensitive C-reactive protein, along with higher levels of brain-derived neurotrophic factor, compared to the control group (P<0.05). No significant difference was observed in the incidence of adverse reactions between the two groups (P>0.05).

The combination of GM and CLO is more effective than CLO monotherapy in improving hemodynamics, enhancing neurological function, and mitigating inflammatory responses in patients with CI complicated by CHD.